The antitrust complaint by Meril against Edwards Lifesciences in the EU could lead to increased legal and regulatory scrutiny. This may result in potential fines, changes in patent practices, or both, negatively impacting EW's market position and financial performance in the short term. The uncertainty surrounding the outcome of such complaints typically leads to negative investor sentiment.